Registered outcomes28

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 20 of 28

List	Outcome	Time frame	Description
Primary	Percentage of Patients with Reactivation Free Survival	12 Months	Stratum I, II, VI
Primary	Response Rate of Second Cycle	9 weeks	Stratum III
Primary	Overall and disease free survival at 1 and 3 years after reduced intensity conditioning hematopoietic stem cell transplantation (RIC-HSCT)	3 Years	Stratum IV
Primary	The cumulative incidence of radiological and clinical neurodegeneration in patients with isolated tumorous CNS-LCH, DI, anterior pituitary dysfunction, and those with CNS-risk lesions	2 Years	Stratum V
Primary	The time interval and cumulative incidence of progression of radiological neurodegeneration to clinically manifested ND-CNS-LCH	2 Years	Stratum V
Primary	Cumulative incidence of specific Permanent Consequences e.g. diabetes insipidus (DI), growth hormone deficiency (GHD), neuropsychological impairment, etc.	2 Years	From all treatment stratum via long-term follow up in Stratum VII
Secondary	Overall Survival	2 Years	Stratum I
Secondary	Number of Participants with Serious and Non-Serious Adverse Events	2 Years
Secondary	Incidence of Permanent Consequences	2 Years	All Stratum
Secondary	Cumulative incidence of reactivations in risk organs	2 Years
Secondary	Time to complete disease resolution	2 Years	Stratum III
Secondary	Response rate to the combination of prednisone, vincristine and cytarabine	2 years	Stratum II
Secondary	The proportion of patients alive and free of disease without permanent consequences (e.g. diabetes insipidus, anterior pituitary dysfunction, radiological or clinical neurodegeneration)	2 Years	Stratum II
Secondary	Percentage of treatment-related toxicities	2 Years	Stratum II
Secondary	Reactivation rates after continuation treatment with Indomethacin vs. 6-MP/MTX.	2 years	Stratum II
Secondary	The type of subsequent intensive and/or maintenance therapy utilized	2 Years	Stratum III
Secondary	Early and late mortality	2 Years	Stratum II
Secondary	Early and late toxicity	2 Years	Stratum III
Secondary	d+100 transplant related mortality	2 Years	Stratum IV
Secondary	Incidence of hematopoietic recovery, and donor chimerism at d+100 and 1 year post RIC-HSCT	2 Years

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02205762/registered

API reference For AI assistants

Registered outcomes28

Sources 3

Read this list from software.